PROM1 and neoplasm: Monitoring of PLuc activity showed an increase in tumor growth by days 63 (CD133) and 77 (OCT4/SOX2), while tumor growth remained inhibited in animals under continued GCV treatment (Fig. 3A,B,D,E).